Literature DB >> 15872256

Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Matthias F C Beersma1, Kristien Dirven, Alje P van Dam, Kate E Templeton, Eric C J Claas, Herman Goossens.   

Abstract

Serology and nucleic acid amplification are the main diagnostic tools for the diagnosis of Mycoplasma pneumoniae infection. Since no reference standard is generally accepted, serologic assays for M. pneumoniae have not been evaluated on a broad scale. In this study, 12 commercially available serologic assays (for immunoglobulin G [IgG] and IgM) and the complement fixation test (CFT) were evaluated by using M. pneumoniae DNA detection by real-time PCR as the "gold standard." The assays tested were Platelia EIA (Bio-Rad), SeroMP EIA (Savyon), Serion classic EIA (Virion/Serion), Biotest EIA (Biotest), Ridascreen EIA (r-Biopharm), AniLabsystems EIA (Labsystems), Novum EIA (Novum Diagnostica), Diagnosys EIA (MP products), Genzyme/Virotech EIA, ImmunoWell EIA (Genbio), ImmunoCard EIA (Meridian), and SerodiaMycoII microparticle agglutination (Fujirebio). Serum samples (n = 46) from 27 PCR-positive patients with a known first day of disease and sera (n = 33) from PCR-negative controls were obtained from prospective studies of acute lower respiratory tract infections. Additionally, control sera (n = 63) from patients with acute viral or bacterial respiratory infections other than those caused by M. pneumoniae were tested. The results showed low specificities for both the Novum and the ImmunoCard IgM assays. The IgM assays with the best performances in terms of sensitivity and specificity were AniLabsystems (77% and 92%, respectively), SeroMP (71% and 88%, respectively), and CFT (65% and 97%, respectively). Good receiver operating characteristic areas under the curve were found for CFT (0.94), the Platelia assay (0.87), and the AniLabsystems assay (0.85). We conclude that there are few commercial serologic assays for the detection of M. pneumoniae infections with appropriate performances in terms of sensitivity and specificity and that PCR has become increasingly important for the diagnosis of M. pneumoniae infections in defined groups of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15872256      PMCID: PMC1153783          DOI: 10.1128/JCM.43.5.2277-2285.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization.

Authors:  J W Dorigo-Zetsma; R P Verkooyen; H P van Helden; H van der Nat; J M van den Bosch
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Indirect enzyme-linked immunosorbent assay for detection of immunoglobulin G reactive with a recombinant protein expressed from the gene encoding the 116-kilodalton protein of Mycoplasma pneumoniae.

Authors:  M F Duffy; K G Whithear; A H Noormohammadi; P F Markham; M Catton; J Leydon; G F Browning
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

3.  Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia.

Authors:  T Watkins-Riedel; G Stanek; F Daxboeck
Journal:  Diagn Microbiol Infect Dis       Date:  2001 May-Jun       Impact factor: 2.803

4.  Multicenter evaluation of the novel enzyme immunoassay based on P1-enriched protein for the detection of Mycoplasma pneumoniae infection.

Authors:  J Suni; R Vainionpää; T Tuuminen
Journal:  J Microbiol Methods       Date:  2001-10       Impact factor: 2.363

5.  Chlamydia pneumoniae and Mycoplasma pneumoniae in children with acute respiratory infection in general practices in The Netherlands.

Authors:  J H Tjhie; J W Dorigo-Zetsma; R Roosendaal; A J Van Den Brule; T M Bestebroer; A I Bartelds; C M Vandenbroucke-Grauls
Journal:  Scand J Infect Dis       Date:  2000

6.  Detection of Mycoplasma pneumoniae in spiked clinical samples by nucleic acid sequence-based amplification.

Authors:  K Loens; D Ursi; M Ieven; P van Aarle; P Sillekens; P Oudshoorn; H Goossens
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Evaluation of four commercial immunoglobulin G (IgG)- and IgM-specific enzyme immunoassays for diagnosis of Mycoplasma pneumoniae infections.

Authors:  J Petitjean; A Vabret; S Gouarin; F Freymuth
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

8.  Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs.

Authors:  J W Dorigo-Zetsma; B Wilbrink; H van der Nat; A I Bartelds; M L Heijnen; J Dankert
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

9.  Effect of age on antibody titer to Mycoplasma pneumoniae.

Authors:  Florian Daxboeck; Karl Kircher; Robert Krause; Harald Heinzl; Christoph Wenisch; Gerold Stanek
Journal:  Scand J Infect Dis       Date:  2002

10.  Improved sensitivity and specificity of enzyme immunoassays with P1-adhesin enriched antigen to detect acute Mycoplasma pneumoniae infection.

Authors:  T Tuuminen; J Suni; M Kleemola; E Jacobs
Journal:  J Microbiol Methods       Date:  2001-02-01       Impact factor: 2.363

View more
  62 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Rare extrapulmonary complications of Mycoplasma pneumoniae infection.

Authors:  Kiran Dhaliwal; Kevin Enright
Journal:  BMJ Case Rep       Date:  2016-02-01

3.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

4.  Mycoplasma pneumoniae in Community-Acquired Lower Respiratory Tract Infections.

Authors:  Surinder Kumar; Indu Bala Garg; Gulshan Rai Sethi
Journal:  Indian J Pediatr       Date:  2018-01-10       Impact factor: 1.967

5.  Comparison of PCR for sputum samples obtained by induced cough and serological tests for diagnosis of Mycoplasma pneumoniae infection in children.

Authors:  Tsutomu Yamazaki; Mitsuo Narita; Nozomu Sasaki; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Clin Vaccine Immunol       Date:  2006-06

6.  Community acquired pneumonia in primary care.

Authors:  Herman Goossens; Paul Little
Journal:  BMJ       Date:  2006-05-06

7.  Mycoplasma pneumoniae infection complicated by necrotizing pneumonitis with massive pleural effusion.

Authors:  Chih-Yung Chiu; Lin-Mei Chiang; Tzu-Ping Chen
Journal:  Eur J Pediatr       Date:  2006-01-19       Impact factor: 3.183

Review 8.  Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections.

Authors:  K Loens; L Van Heirstraeten; S Malhotra-Kumar; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2008-11-19       Impact factor: 5.948

9.  Isothermal Detection of Mycoplasma pneumoniae Directly from Respiratory Clinical Specimens.

Authors:  Brianna L Petrone; Bernard J Wolff; Alexandra A DeLaney; Maureen H Diaz; Jonas M Winchell
Journal:  J Clin Microbiol       Date:  2015-07-15       Impact factor: 5.948

Review 10.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.